Laurus Labs gets two observations from USFDA for its Unit 2

Our Bureau | | Updated on: Nov 08, 2019
image caption

Laurus Labs Ltd has completed the US Food and Drug Administration (USFDA) inspection of its Unit – 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh with two observations.

“The observations are in procedural in nature,’’ the Hyderabad-based Laurus said in a release.

This was a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from November 4-8, the company said.

Laurus Labs scrip lost 0.78 per cent to end at ₹366.90 on the BSE on Friday.

Published on November 08, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you